Table 1

Characteristics of included studies

Author/yearDesignSample sizeAge
(mean)
Baseline seropositivity rate
(at least one serotype (%))
InterventionControlOutcomes
Leo et al 30
2012
Randomised controlled trial (RCT)
phase 2
38611.318.5Recombinant tetravalent dengue vaccine (CYD-TDV)PlaceboImmunogenicity
Safety
Sabchareon et al 31
2012
RCT
phase 2
36738.270CYD-TDVPlacebo
Rabies vaccine
Efficacy
Immunogenicity
Safety
Tran et al 32
2012
RCT
phase 2
1508.838.5CYD-TDVPlacebo
Meningococcal
Polysaccharide typhoid Vi
Immunogenicity
Safety
Lanata et al 34
2012
RCT
phase 2
2896.341CYD-TDVPneumococcal polysaccharideImmunogenicity
Safety
Dayan et al 28
2013
RCT
phase 2
13512.770CYD-TDVPlaceboImmunogenicity
Safety
HSS et al 29
2013
RCT
phase 3
2466.446CYD-TDVPlaceboImmunogenicity
Safety
Villar et al 33
2013
RCT
phase 2
54412.576.5CYD-TDVPlacebo
Tetanus
Diphtheria
Acellular pertussis
Immunogenicity
Safety
Capeding et al 35
2014
RCT
phase 3
10 0608.868CYD-TDVPlaceboEfficacy
Safety
Villar et al 36
2015
RCT
phase 3
18 77412.479.4CYD-TDVPlaceboEfficacy
Safety